Cosentyx (secukinumab) is a biologic medication that is used to treat certain autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. However, it is not approved for the treatment of other autoimmune diseases.

A study published in the Journal of Clinical and Diagnostic Research evaluated the effectiveness of Cosentyx in treating Behcet's disease, which is an autoimmune disorder that affects multiple organs [3]. The study found that Cosentyx was effective in treating the skin and mucous membrane manifestations of Behcet's disease. However, further research is needed to determine its effectiveness in treating other manifestations of the disease.

Another study published in the Journal of Rheumatology investigated the efficacy of Cosentyx in treating rheumatoid arthritis, which is another autoimmune disease [2]. The study found that Cosentyx did not demonstrate significant efficacy in treating rheumatoid arthritis, and further research is needed to determine its effectiveness in treating other autoimmune diseases.

In conclusion, Cosentyx is only approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis. While there is some evidence that it may be effective in treating other autoimmune diseases such as Behcet's disease, further research is needed to determine its efficacy in treating these conditions [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://pubmed.ncbi.nlm.nih.gov/23253932/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013855/